NAD+
(Synonyms: 烟酰胺腺嘌呤双核苷酸) 目录号 : GC17216NAD+是一种转递氢离子的辅酶,参与许多酶促反应,由核糖基烟酰胺5'-二磷酸通过焦磷酸键与5'-磷酸腺苷偶联组成。
Cas No.:53-84-9
Sample solution is provided at 25 µL, 10mM.
NAD+ is a coenzyme that transfers hydrogen ions and participates in many enzymatic reactions. It is composed of ribosyl nicotinamide 5'-diphosphate coupled to 5'-adenosine phosphate through a pyrophosphate bond[1]. NAD+ is the oxidized form of nicotinamide adenine dinucleotide (NAD), and the reduced form of NAD is NADH. The intracellular NAD+/NADH reflects the metabolic activity and health of the cell[2]. NAD+ is a key redox carrier that plays an irreplaceable role in glycolysis, gluconeogenesis, tricarboxylic acid cycle and respiratory chain[3]. NAD+ is also a substrate of the nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1)[4].
In vitro, NAD+ (100µM) treatment of naive CD4+ T cells for 72h induced naive CD4+ T cells to produce a large amount of cytokines, promoted cell differentiation into helper T cells (Th1, Th2 and Th17 cells), but prevented differentiated cells from producing cytokines[5].
In vivo, intravenous administration of NAD+ (10, 60 mg/kg) to ART2−/− and wild-type (WT) mice reduced the inhibitory effect of CD4+ CD25+ FoxP3+ regulatory T cells (T reg cells) in WT mice in a dose-dependent manner, but had no effect on the T reg cell function in ART2−/− mice. It also regulated the size and phenotype of the T reg cell pool in vivo[6]. Intravenous administration of NAD+ (10-20 mg/kg) to rats subjected to ischemia/reperfusion (I/R) dose-dependently reduced I/R-induced myocardial infarction, reduced the levels of TUNNEL signaling, Box and cleaved caspase-3, and increased Bcl-XL levels[7].
References:
[1] Pietrowska-Borek M, Dobrogojski J, Sobieszczuk-Nowicka E, et al. New insight into plant signaling: extracellular ATP and uncommon nucleotides[J]. Cells, 2020, 9(2): 345.
[2] Belenky P, Bogan K L, Brenner C. NAD+ metabolism in health and disease[J]. Trends in biochemical sciences, 2007, 32(1): 12-19.
[3] Guo C, Huang Q, Wang Y, et al. Therapeutic application of natural products: NAD+ metabolism as potential target[J]. Phytomedicine, 2023, 114: 154768.
[4] Alano C C, Tran A, Tao R, et al. Differences among cell types in NAD+ compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes[J]. Journal of neuroscience research, 2007, 85(15): 3378-3385.
[5] Tullius S G, Biefer H R C, Li S, et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation[J]. Nature communications, 2014, 5(1): 5101.
[6] Hubert S, Rissiek B, Klages K, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2–P2X7 pathway[J]. Journal of Experimental Medicine, 2010, 207(12): 2561-2568.
[7] Zhang Y, Wang B, Fu X, et al. Exogenous NAD+ administration significantly protects against myocardial ischemia/reperfusion injury in rat model[J]. American journal of translational research, 2016, 8(8): 3342.
NAD+是一种转递氢离子的辅酶,参与许多酶促反应,由核糖基烟酰胺5'-二磷酸通过焦磷酸键与5'-磷酸腺苷偶联组成[1]。NAD+是氧化形式的烟酰胺腺嘌呤二核苷酸(NAD),NAD还原形式为NADH,细胞内NAD+/NADH反映了细胞的代谢活性和健康状况[2]。NAD+是一种关键的氧化还原载体,它在糖酵解、糖异生、三羧酸循环及呼吸链中发挥着不可替代的作用[3]。NAD+也是核酶聚(ADP-核糖)聚合酶-1(PARP-1)的底物[4]。
在体外,NAD+(100µM)处理幼稚CD4+ T细胞72h,诱导幼稚CD4+ T细胞产生大量细胞因子,促进细胞分化为辅助T细胞(Th1、Th2和Th17细胞),但阻止分化细胞产生细胞因子[5]。
在体内,NAD+(10, 60mg/kg)通过静脉注射处理ART2−/−和野生型(WT)小鼠,以剂量依赖性方式降低了WT小鼠CD4+ CD25+ FoxP3+调节性T细胞 (T reg 细胞)的抑制作用,而对ART2−/−小鼠的T reg细胞功能没有影响,还可以调节体内T reg细胞池的大小和表型[6]。NAD+(10-20mg/kg)通过静脉注射治疗缺血/再灌注(I/R)大鼠,剂量依赖性地减少I/R诱发的心肌梗塞,降低TUNNEL信号、Box和裂解caspase-3的水平,并增加Bcl-XL水平[7]。
Cell experiment [1]: | |
Cell lines | CD4+ T cells |
Preparation Method | CD4+ T cells were isolated from mouse spleens, 100μM NAD+ was added to the culture medium of the treated cells, and cell function and differentiation analysis was performed 72 hours after treatment. |
Reaction Conditions | 100μM; 72 h |
Applications | NAD+ converts naïve CD4+ T cells into Th1 and Th2 as well as Th17 cells. NAD+ induces a robust cytokine production in naïve CD4+ T cells but blocks cytokine production in differentiated cells. |
Animal experiment [2]: | |
Animal models | ART2−/−、 WT mice |
Preparation Method | Mice were treated i.v. with 10 or 60 mg NAD+ in 100–200µl PBS solution adjusted to pH 7.4. 24h later, single-cell suspensions prepared from LN, spleen, and blood were analyzed by flow cytometry. |
Dosage form | 10 or 60mg/kg;i.v. |
Applications | Exogenous NAD+ reduced the suppressive effect of WT mice CD4+ CD25+ FoxP3+ regulatory T cells (T reg cells) cells in a dose-dependent manner, whereas it had no effect on the function of T reg cells from ART2−/− mice. Exogenous NAD+ can modulate the size and the phenotype of the T reg cell pool in vivo. |
References: [1] Tullius S G, Biefer H R C, Li S, et al. NAD+ protects against EAE by regulating CD4+ T-cell differentiation[J]. Nature communications, 2014, 5(1): 5101. [2] Hubert S, Rissiek B, Klages K, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2–P2X7 pathway[J]. Journal of Experimental Medicine, 2010, 207(12): 2561-2568. |
Cas No. | 53-84-9 | SDF | |
别名 | 烟酰胺腺嘌呤双核苷酸 | ||
化学名 | [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate | ||
Canonical SMILES | C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)([O-])OP(=O)(O)OCC3C(C(C(O3)N4C=NC5=C4N=CN=C5N)O)O)O)O)C(=O)N | ||
分子式 | C21H27N7O14P2 | 分子量 | 663.43 |
溶解度 | ≥ 28.55mg/mL in Water | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.5073 mL | 7.5366 mL | 15.0732 mL |
5 mM | 0.3015 mL | 1.5073 mL | 3.0146 mL |
10 mM | 0.1507 mL | 0.7537 mL | 1.5073 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet